Nikitin Alexey G, Chistiakov Dimitry A, Minushkina Larissa O, Zateyshchikov Dmitry A, Nosikov Valery V
Department of Molecular Diagnostics, National Research Center GosNIIgenetika, 1st Dorozhny proezd 1, 117545 Moscow, Russia.
Heart Vessels. 2010 May;25(3):229-36. doi: 10.1007/s00380-009-1159-9. Epub 2010 May 29.
Abnormalities in lipid metabolism and enhanced oxidative stress are considered as major risk factors for coronary atherosclerosis. Functional genetic variations in genes whose products are involved in lipid metabolism and antioxidant defense could therefore modulate risk of coronary artery disease (CAD). In this study, we evaluate whether the PPARGC1A Gly482Ser, PPARG3 (-681)C/G, PPARD +294T/C, and CYBA +242C/T gene variants confer the risk of CAD in a Russian population. A total of 313 CAD patients and 132 controls with no clinical sign of CAD were studied. The polymorphic markers were tested using a TaqMan assay. Allele and genotype frequencies in CAD patients and controls were compared using the Yates chi(2) test. Association of the genetic markers with metabolic risk factors of arterial atherosclerosis was studied using the analysis of variance test and then adjusted for conventional risk factors in the multiple regression analysis. For CYBA +242C/T, both the allele T and genotype T/T showed significant association with higher risk of CAD (odds ratio =1.49 and 3.89, respectively). The allele C and genotype C/C of the +294T/C marker of PPARD were associated with increased risk of CAD providing an odds ratio of 2.12 and 2.78, respectively. The risk variants of CYBA +242C/T and PPARD +294T/C markers were associated with higher low-density lipoprotein cholesterol and increased total serum cholesterol, respectively. In conclusion, the CYBA +242C/T and PPARD +294T/C variants modulate risk of CAD through their associations with atherogenic serum lipid profiles.
脂质代谢异常和氧化应激增强被认为是冠状动脉粥样硬化的主要危险因素。因此,其产物参与脂质代谢和抗氧化防御的基因中的功能性遗传变异可能会调节冠状动脉疾病(CAD)的风险。在本研究中,我们评估PPARGC1A Gly482Ser、PPARG3 (-681)C/G、PPARD +294T/C和CYBA +242C/T基因变异是否会增加俄罗斯人群患CAD的风险。共研究了313例CAD患者和132例无CAD临床症状的对照者。使用TaqMan分析法检测多态性标记。使用Yates卡方检验比较CAD患者和对照者的等位基因和基因型频率。使用方差分析研究遗传标记与动脉粥样硬化代谢危险因素的关联,然后在多元回归分析中对传统危险因素进行校正。对于CYBA +242C/T,等位基因T和基因型T/T均与较高的CAD风险显著相关(优势比分别为1.49和3.89)。PPARD的+294T/C标记的等位基因C和基因型C/C与CAD风险增加相关,优势比分别为2.12和2.78。CYBA +242C/T和PPARD +294T/C标记的风险变异分别与较高的低密度脂蛋白胆固醇和总血清胆固醇升高相关。总之,CYBA +242C/T和PPARD +294T/C变异通过与致动脉粥样硬化的血清脂质谱相关联来调节CAD风险。